Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Virus-like particles (VLPs) consist of one or more viral coat proteins that assemble into particles. They can be taken up by antigen presenting cells (APC), peptides derived from them are presented on MHC class I molecules at the cell surface, and thereby prime a CD8+ T cell response, either against the particle-forming protein itself (such as Hepatitis B surface antigen) or additional peptide sequences that are produced as fusions with the particle-forming protein. This article describes the preparation of Ty-VLPs in Saccharomyces cerevisiae, a system that can easily be handled in the laboratory or scaled up for manufacture, and is safe in use.

Original publication




Journal article


Mol Biotechnol

Publication Date





169 - 177


Adjuvants, Immunologic, Animals, Base Sequence, CD8-Positive T-Lymphocytes, DNA Primers, Electrophoresis, Polyacrylamide Gel, Epitopes, Epitopes, T-Lymphocyte, Mice, Mice, Inbred BALB C, Molecular Sequence Data, Plasmids, Plasmodium berghei, Saccharomyces cerevisiae, Vaccination, Vaccines, Synthetic, Viral Vaccines, Viruses